EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NeuBase Therapeutics's Enterprise Value is $-5.66 Mil.
NeuBase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-13.73 Mil. Therefore, NeuBase Therapeutics's EV-to-EBIT for today is 0.41.
The historical rank and industry rank for NeuBase Therapeutics's EV-to-EBIT or its related term are showing as below:
NBSE'
s EV-to-EBIT Range Over the Past 10 Years
Min: -9.9 Med: 0 Max: 12.66
Current: 0.41
During the past 13 years, the highest EV-to-EBIT of NeuBase Therapeutics was 12.66. The lowest was -9.90. And the median was 0.00.
NBSE's EV-to-EBIT is ranked better than 80.86% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs NBSE: 0.41
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NeuBase Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $-3.99 Mil.
NeuBase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-13.73 Mil. NeuBase Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 343.87%.
NeuBase Therapeutics EV-to-EBIT Historical Data
The historical data trend for NeuBase Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NeuBase Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuBase Therapeutics EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NeuBase Therapeutics's EV-to-EBIT falls into.
NeuBase Therapeutics EV-to-EBIT Calculation
NeuBase Therapeutics's EV-to-EBIT for today is calculated as:
NeuBase Therapeutics's current Enterprise Value is $-5.66 Mil.
NeuBase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NeuBase Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $-3.99 Mil.
NeuBase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuBase Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of NeuBase Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
NeuBase Therapeutics (NeuBase Therapeutics) Business Description
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBSE has been successfully added to your 